Balance Sheet
AssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Genmab A (GNMSF) Finished Goods (2023 - 2025)

Historic Finished Goods for Genmab A (GNMSF) over the last 3 years, with Q4 2025 value amounting to $13.0 million.

  • Genmab A's Finished Goods rose 1818.18% to $13.0 million in Q4 2025 from the same period last year, while for Dec 2025 it was $13.0 million, marking a year-over-year increase of 1818.18%. This contributed to the annual value of $13.0 million for FY2025, which is 1818.18% up from last year.
  • As of Q4 2025, Genmab A's Finished Goods stood at $13.0 million, which was up 1818.18% from $11.0 million recorded in Q4 2024.
  • In the past 5 years, Genmab A's Finished Goods registered a high of $13.0 million during Q4 2025, and its lowest value of $9.0 million during Q4 2023.
  • Moreover, its 3-year median value for Finished Goods was $11.0 million (2024), whereas its average is $11.0 million.
  • As far as peak fluctuations go, Genmab A's Finished Goods soared by 2222.22% in 2024, and later surged by 1818.18% in 2025.
  • Genmab A's Finished Goods (Quarter) stood at $9.0 million in 2023, then increased by 22.22% to $11.0 million in 2024, then rose by 18.18% to $13.0 million in 2025.
  • Its last three reported values are $13.0 million in Q4 2025, $11.0 million for Q4 2024, and $9.0 million during Q4 2023.